

*Kymriah is currently available through the public hospital system for patients with acute lymphoblastic leukaemia following an assessment and recommendation earlier this year from the Medical Services Advisory Committee (MSAC). The MSAC is currently considering an application from Novartis to expand access to Kymriah to patients with certain types of lymphoma.*

*While Novartis has yet to agree to provide compassionate access whilst their application is being considered by MSAC, we will continue with every fibre to urge them to support Mr Roberts.*

*The Government also provides funding through the Medical Treatment Overseas Program (MTO) for patients to access treatment that is not available in Australia.*

Spokesperson for Health Minister, Greg Hunt. September 2019